<DOC>
	<DOCNO>NCT00566215</DOCNO>
	<brief_summary>Based surgery technique study non-obese diabetic mouse model Rubino Marescaux ( 2004 ) , wich reverse diabetes animal , perform previous study human volunteer type 2 diabetes overweight ( non-obese ) . The surgery duodenal exclusion wich stomach volume keep intact . We observe improvement glycemic control hemoglobin A1c , ally reduction medicine : insulin withdrawn significantly lower . Further improvement diabetes could achieve intervention insulin resistance , another factor diabetes pathophysiology . As factor related visceral fat , hypothesize surgical removal major omentum , great component central adiposity , could beneficial . This study evaluate mechanism amelioration type 2 diabetes mellitus duodenal exclusion surgery plus total omentectomy , method standardize meal stimulus insulin tolerance test , human non-obese volunteer diabetes type 2 know insulin secretion capacity . The previously study volunteer submit duodenal exclusion without omentectomy control group .</brief_summary>
	<brief_title>Treatment Type 2 Diabetes Mellitus Duodenal Exclusion Associated With Omentectomy : Clinical Hormonal Study</brief_title>
	<detailed_description>Diabetes reversion observe bariatric surgery even significant weight loss could explain , mainly predominantly malabsorptive procedure , follow combine malabsorption gastric restriction . Changes hormonal communication digestive system ( incretins ) pancreas would explain antidiabetogenic role surgery , effect could obtain nonobese , diabetic individual . Based surgery technique study non-obese diabetic mouse model Rubino Marescaux ( 2004 ) , wich reverse diabetes animal , perform previous study human volunteer type 2 diabetes overweight ( non-obese ) . The surgery duodenal exclusion : stomach volume keep intact , maintain caloric ingestion weight reduces le 5 % , without potential nutritional deprivation commonly see bariatric surgery . We observe improvement glycemic control hemoglobin A1c , ally reduction medicine : insulin withdrawn significantly lower . An standardized mixed meal tolerance test show favorable change gastrointestinal hormone stimulate insulin secretion ( incretins ) : increase GLP-1 reduction GIP . Further improvement diabetes could achieve intervention insulin resistance , another factor diabetes pathophysiology . As factor related visceral fat , hypothesize surgical removal major omentum , great component central adiposity , could beneficial . In fact , surgical removal visceral fat rodent improve insulin sensitivity . A pilot study human , obese volunteer submit gastric adjustable band promise int aspect . This study evaluate mechanism amelioration type 2 diabetes mellitus duodenal exclusion surgery plus total omentectomy , method standardize meal stimulus insulin tolerance test , human non-obese , volunteer diabetes type 2 know insulin secretion capacity . The previously study volunteer submit duodenal exclusion without omentectomy control group .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<criteria>Age : 18 60 year . BMI 25 29,9 kg/mÂ² . Weight variance le 5 % last 3 month . Previous diagnosis diabetes type 2 . Insulin requirement , alone along oral agent Capacity understand procedure study . To agree voluntarily participate study , sign informed consent . Positive AntiGAD antibody Laboratorial signal probable failure insulin production , i. e. , seric peptide C lesser 1 ng/mL . History hepatic disease like cirrhosis chronic active hepatitis . Kidney dysfunction ( creatinine &gt; 1,4 mg/dl woman &gt; 1,5 mg/dl men ) . Hepatic dysfunction : ALT and/or AST 3x upper normal limit . Recent history neoplasia ( &lt; 5 year ) . Use oral injectable corticosteroid consecutive 14 day last three month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>diabetes mellitus , type 2</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Intra-Abdominal Fat</keyword>
	<keyword>Omentum</keyword>
	<keyword>duodenal exclusion</keyword>
	<keyword>bariatric surgery</keyword>
	<keyword>Glucagon-Like Peptide 1</keyword>
	<keyword>Gastric Inhibitory Polypeptide</keyword>
	<keyword>insulin</keyword>
	<keyword>glucagon</keyword>
	<keyword>ghrelin</keyword>
	<keyword>adiponectin</keyword>
	<keyword>Cytokines</keyword>
</DOC>